Warum so wenige Threads über IMPATH??? - 500 Beiträge pro Seite

[SPIRIT]

alle reden nur von antisoma hin antisoma her
so ein scheiss
impath gehört euch ans herz gelegt
hier die zahlen
IMPATH Announces Record Third Quarter ResultsRecord Revenues for Twenty-Seventh Consecutive Quarter; Revenues Increase 64%, Operating Income Increases 66% and BioPharma/Genomics Revenues Increase 97% Over Third Quarter `99 Figures
IMPH

NEW YORK, Oct 24, 2000 /PRNewswire via COMTEX/ -- IMPATH Inc. (Nasdaq: IMPH ) today announced record results for the third quarter ended September 30, 2000, marking the Company`s twenty-seventh consecutive quarter of record revenues.

The Company reported revenues of $35,406,000 for the third quarter, a 64% increase over third quarter 1999 revenues of $21,543,000. Operating income for the third quarter was $6,080,000, an increase of 66% over $3,656,000 for the same period a year ago. Operating margin increased to 17.2% of revenues from 16.8% in the second quarter of 2000. Earnings before interest (income and expense), taxes, depreciation and amortization ("EBITDA") for the period were $8,812,000, a 60% increase over third quarter EBITDA of $5,521,000 in 1999. Net income of $3,306,000 was reported during the third quarter, an increase of 37% compared with net income of $2,406,000 in the year ago period. Earnings per diluted share were $.20, a 33% increase over third quarter 1999 earnings per diluted share of $.15 (split adjusted after taking into account the 2-for-1 stock split the Company effected in the form of a 100% stock dividend effective August 28, 2000).

For the third quarter, the Company had approximately 16,499,000 weighted average common and common equivalent shares outstanding compared with 16,282,000 for the third quarter of 1999 (split adjusted).

For the nine months ended September 30, 2000, the Company reported revenues of $99,332,000, a 67% increase over revenues for the first nine months of 1999 of $59,359,000, and operating income of $16,494,000, a 74% increase over $9,459,000 in the first nine months of the prior year. EBITDA for the nine months ended September 30, 2000 were $24,150,000, a 69% increase over EBITDA of $14,299,000 for the first nine months of 1999. Net income for the period was $9,195,000, representing a 42% increase over $6,494,000 for the comparable period in 1999. Earnings per diluted share for the nine months were $.57, a 43% increase over $.40 per share in the comparable period of 1999 (split adjusted).

The Company had approximately 16,169,000 weighted average common and common equivalent shares outstanding for the nine months ended September 30, 2000, compared with 16,384,000 for the same period in 1999 (split adjusted).

Commenting on the results, Dr. Anu D. Saad, President and Chief Executive Officer of IMPATH, said, "In our 27th consecutive quarter of record revenues, we again demonstrated the fundamental strength of our business. This strong performance was achieved even as we have begun to accelerate our investment in building infrastructure to support the demand for our services, particularly in the oncology drug discovery and development arena. These activities include expanding our tissue procurement network by increasing the number of clinical and physician sites for our `Genebank(TM)` program, developing new technologies such as `OptimArray(TM)`, a high throughput technique to assist companies in validating targets, and enhancing our database capabilities to insure maximum flexibility in data acquisition, processing and dynamic inquiry response for the end-user. In order to maximize the opportunities for IMPATH in the rapidly evolving oncology drug development area, in 2001 we intend to form a wholly-owned subsidiary, IMPATH Predictive Oncology(TM), the `solutions provider in oncology drug discovery and development`, offering the seamless integration of our enhanced services in the pharmacogenomic marketplace.

"For the three months ended September 30, 2000, our BioPharmaceutical/Genomics Services grew 97% compared to the three month period a year ago. Shortly after the close of the quarter, we announced an agreement with Bristol-Myers Squibb that formalized a relationship between our two companies. This was the second of such agreements; the first being our announcement of a relationship with Millennium Pharmaceuticals earlier in the quarter. Under each agreement, we will be providing a broad range of drug development support tools including access to drug resistance analysis utilizing cancerous tissue, molecular profiling and outcomes information to assist the companies in their product development efforts.

"IMPATH Physicians Network ("IPN"), which recruits patients and manages clinical trials in the offices of community-based oncologists, also made significant strategic progress during the quarter. IPN is actively recruiting qualified patients for cancer clinical trials for several pharmaceutical companies including Bristol-Myers Squibb, Lilly, Genentech and Immunomedics.

"During the quarter, our Physician Services` revenue grew 65%, with case volume expanding 23%, over the comparable period in 1999. We continue to see strong demand for our state-of-the-art technologies and medical expertise in providing diagnostic, prognostic and treatment defining information to community-based physicians around the country. Driven by recent scientific advancements, we will be offering several new products utilizing multiple technologies for prognosis and therapeutic response, including new analyses for colon cancer."

"As we expand our capabilities, establish innovative product platforms, pursue new relationships and agreements, gain recognition for our important oncology resources and build the requisite internal structure to support the anticipated growth, these activities will positively impact our Physician Services area. By playing a larger role in accelerating the drug discovery and development process, and as new targeted therapies become a reality, we will increase the demand for prognostic services provided by our core business," added Richard Adelson, the Company`s Chief Operating Officer.

"We are very encouraged by our progress and remain dedicated to our role as the comprehensive resource in cancer, while continuing to maximize shareholder value," Dr. Saad concluded.

The Company advised that its intensive efforts to lower its accounts receivable days sales outstanding (DSOs) resulted in DSOs for the period decreasing to 118 days from 132 days at the end of the third quarter of 1999.

Additionally, the Company stated that at a Special Meeting of Shareholders held on October 23, 2000, its shareholders approved an increase in the number of authorized shares of common stock from 20,000,000 to 50,000,000 shares.

IMPATH Inc. is in the business of improving outcomes for cancer patients. The Company is the leading source of cancer information and analyses with a database of more than 650,000 analyzed cases to date. IMPATH uses sophisticated technologies to provide patient-specific cancer diagnostic and prognostic information to pathologists, oncologists and transplant centers. IMPATH currently serves more than 7,400 physicians specializing in the treatment of cancer patients, in over 1,785 hospitals and 409 oncology practices. Utilizing its comprehensive resources, IMPATH is also working with pharmaceutical, biotechnology and genomics companies involved in developing new therapeutics targeted to specific, biological characteristics of cancer.




der kurs notiert auf ATH und das fast jeden tag
und mit einer marktkapitalisierung von 1,2 milliarden $
sicher nicht zu teuer
darum auch der anstieg das ganze jahr über

BEI KAUF AUF JEDEN FALL STOP LOSS ORDER SETZEN!!!!!!!!!!
würd sagen ca 10% unter einkaufskurs der wert hat selten
soviel verloren bei seinem anstieg

[SPIRIT]

das gibts echt nicht
ihr seid antisoma-narrisch

euch ist nicht zu helfen

gerade heute super einstiegszeitpunkt
am montag gehts auf ein neues ATH

[pollyanna]

Hallo Spirit,
Aktien die immer weiter steigen und trotzdem nicht von der Masse beachtet werden sind die richtigen Perlen.
Der Gentleman-Aktionär genießt und schweigt.
Ich habe Impath auch schon einige Zeit in meinem Depot.
Es gibt aber leider neben den Biotechfondmanagern nur wenige Aktionäre, die den Wert der größten Krebspatientendatenbank von Impath und die Zukunftsaussichten der Erkenntnisse die daraus gewonnen werden können, einschätzen können. Impath ist Gold wert für die großen Pharmamultis. Das ist aber für einen Herrn Förtsch zu schwierig zu vermitteln.
Ich persönlich werde immer vorsichtig wenn zu viele threads über eine Aktie entstehen. Dadurch konnte ich bei AMD z.b. noch rechtzeitig austeigen.
Aber Glückwunsch zu deiner Entdeckung. Denn welcher Biotechwert mit so einer Kursentwicklung kann schon Gewinne vorweisen und einen KGV von gerade mal 111 momentan.


Gruß pollyanna